ThaiPR.NET https://www.thaipr.net/location/beijing-and-bridgewater-n-j Press Release Distribution Center of Thailand Thu, 30 Apr 2026 18:05:11 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18]]> https://www.thaipr.net/en/health_en/3166824 Fri, 11 Mar 2022 12:55:00 +0700 health_en https://www.thaipr.net/en/health_en/3166824 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, single, ascending dose clinical study in the U.S. for the company’s investigational drug, GZR18. GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) […]

The post Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18 appeared first on ThaiPR.NET.

]]> <![CDATA[Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18]]> https://www.thaipr.net/en/health_en/3131848 Wed, 08 Dec 2021 18:15:14 +0700 health_en https://www.thaipr.net/en/health_en/3131848 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company’s compound, GZR18, to improve the management of type 2 diabetes mellitus. The investigational compound, GZR18, is […]

The post Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18 appeared first on ThaiPR.NET.

]]> <![CDATA[Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)]]> https://www.thaipr.net/en/health_en/3109784 Fri, 15 Oct 2021 09:20:11 +0700 health_en https://www.thaipr.net/en/health_en/3109784 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic. The two studies were conducted separately in subjects with type 1 (n=576) and type […]

The post Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA) appeared first on ThaiPR.NET.

]]> <![CDATA[Gan & Lee Pharmaceuticals to present recent data at the 57th Annual European Association for the Study of Diabetes Meeting]]> https://www.thaipr.net/en/health_en/3096580 Thu, 09 Sep 2021 15:00:17 +0700 health_en https://www.thaipr.net/en/health_en/3096580 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five recent abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes (EASD) Meeting. The meeting will be held virtually from September 27th – […]

The post Gan & Lee Pharmaceuticals to present recent data at the 57th Annual European Association for the Study of Diabetes Meeting appeared first on ThaiPR.NET.

]]> <![CDATA[Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma]]> https://www.thaipr.net/en/health_en/3045335 Thu, 08 Apr 2021 09:30:30 +0700 health_en https://www.thaipr.net/en/manufacturing_en/3045335 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma. Glioma is a broad term describing neuroepithelial tumors […]

The post Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma appeared first on ThaiPR.NET.

]]> <![CDATA[Gan & Lee Announces New Partnership with International Diabetes Federation]]> https://www.thaipr.net/en/health_en/3031346 Tue, 23 Feb 2021 08:15:25 +0700 health_en https://www.thaipr.net/en/health_en/3031346 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, has announced a collaborative partnership with the International Diabetes Federation (IDF) that aims to support their global efforts of promoting diabetes care and prevention worldwide. This collaboration will allow opportunities to support future initiatives such as medical […]

The post Gan & Lee Announces New Partnership with International Diabetes Federation appeared first on ThaiPR.NET.

]]> <![CDATA[Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA]]> https://www.thaipr.net/en/general_en/3025873 Fri, 05 Feb 2021 08:30:17 +0700 general_en https://www.thaipr.net/en/general_en/3025873 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee […]

The post Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA appeared first on ThaiPR.NET.

]]>